BioCentury | Jun 2, 2020

Hillhouse-backed $160M series B round to drive Genor’s first candidate to the market

Genor plans to establish a commercial team and take its first checkpoint inhibitor to market for a new indication after raising a $160 million series B round led by existing investor Hillhouse Capital. New investors...
BioCentury | Jun 2, 2020
Product Development

Phase I start marks first for anti-SARS-CoV-2 mAbs, first for AbCellera

A COVID-19 mAb from Eli Lilly and AbCellera has become the first against the virus to start human trials and is also the Vancouver-based company’s first product to enter the clinic. While the Phase I...
BioCentury | Apr 16, 2020
Product Development

April 15 Quick Takes: TScan, Novartis team up on TCR therapies and a first for UroGen; plus Aligos, Leo, Madrigal, Merck

TScan, Novartis partner to develop TCR therapies  TScan Therapeutics Inc. entered an agreement with Novartis AG (NYSE:NVS; SIX:NOVN) to discover and develop TCR-engineered T cell therapies. Novartis will pay a technology access fee and research...
BioCentury | Mar 24, 2020
Product Development

March 23 COVID-19 roundup: Gilead looks to expand access to remdesivir, antiviral gains Orphan designation; plus N.Y.’s chloroquine trial, Celltrion and more

As Gilead begins shifting its individual compassionate use authorizations for COVID-19 candidate remdesivir to broader expanded access programs, the antiviral was granted Orphan Drug designation Monday. The day also saw several companies begin work on...
BioCentury | Mar 16, 2020
Product Development

Teva, Celltrion launch fourth U.S. Herceptin biosimilar at modest discount

Teva and Celltrion Monday launched Herzuma trastuzumab-pkrb, a biosimilar version of Genentech’s Herceptin trastuzumab, in the U.S. at a 10% discount to the original product. The launch price suggests that unlike generic drugs, the launch...
BC Extra | Jan 25, 2020
Company News

Pfizer seeking to dent market share with trio of discounted biosimilars

Pfizer is hoping that discounts of 22-24% from reference drugs’ wholesale acquisition costs (WACs) will help it gain market share for three new or soon-to-be launched biosimilars, each of which will compete with at least...
BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

Ten years after the U.S. created a pathway for biosimilars--and four and a half years after the first FDA approval--a few manufacturers have demonstrated that they can overcome the technical, regulatory and commercial barriers to...
BC Extra | Nov 26, 2019
Company News

Nov. 26 Company Quick Takes: Kyowa, Ardelyx expand partnership; plus ICER, Celltrion, Asahi-Veloxis and Merck

Kyowa, Ardelyx expand collaboration with new targets and $20M investment  Under an expanded partnership, Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) will pay Ardelyx Inc. (NASDAQ:ARDX) $10 million in research support over the next two years...
BC Extra | Sep 18, 2019
Financial News

Hong Kong’s first IPO in months values Shanghai Henlius at $3.4B

Amid market concerns due to recent Hong Kong protests, Shanghai Henlius became the first company to list on the exchange’s biotech chapter in four months Wednesday, raising HK$3.2 billion ($409.9 million) in an IPO that...
BC Innovations | Jul 25, 2019
Distillery Therapeutics

Innate Pharma's trifunctional NK cell engagers for multiple cancers

DISEASE CATEGORY: Cancer INDICATION: Lung cancer; lymphoma; solid tumors Innate Pharma S.A. showed that its trifunctional NK cell engager platform could be deployed against lymphoma, lung cancer and solid tumors. The trifunctional NK cell engagers...
Items per page:
1 - 10 of 233